Given the correlations between HER2 amplification and PD‐L1 expression, and genomic and immune landscapes, we also investigated the impacts of HER2 amplification and PD‐L1 expression on overall prognosis in patients with surgically resected GC. The gene discussed is ERBB2; the disease is gastric cancer.